BAM
AKBA icon

Belpointe Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Belpointe Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,243
Closed -$1.26K – 685
2023
Q1 		$1.26K Hold
2,243
– – ﹤0.01% 3431
2022
Q4 		$1.29K Buy
+2,243
New +$703 ﹤0.01% 3384

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Belpointe Asset Management's AKBA Position: Q2 2023 in Review

Belpointe Asset Management sold out of Akebia Therapeutics (AKBA) in Q2 2023, closing a stake of 2,243 shares — an estimated $1.26K sold.

Belpointe Asset Management first reported a position in AKBA in Q4 2022 and held it in 2 quarters. The position peaked at $1.29K in Q4 2022. 79 funds tracked by Wall St. Rank hold AKBA as of Q2 2023.

  • Belpointe Asset Management reported no remaining Akebia Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 2,243 Akebia Therapeutics shares in Q2 2023, an estimated $1.26K.
  • Belpointe Asset Management first reported a position in Akebia Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Akebia Therapeutics position peaked at $1.29K in Q4 2022.
  • 79 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.